Edition:
India

ARCA Biopharma Inc (ABIO.OQ)

ABIO.OQ on NASDAQ Stock Exchange Capital Market

4.19USD
25 Nov 2020
Change (% chg)

-- (--)
Prev Close
$4.19
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
111,565
52-wk High
$22.00
52-wk Low
$2.21

Latest Key Developments (Source: Significant Developments)

Arca Biopharma Announces FDA Approval Of IND Application For Ab201 As A Potential Treatment For Covid-19
Wednesday, 7 Oct 2020 

Oct 7 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA ANNOUNCES FDA APPROVAL OF IND APPLICATION FOR AB201 AS A POTENTIAL TREATMENT FOR COVID-19.ARCA BIOPHARMA INC - INITIATION OF PHASE 2B CLINICAL TRIAL ANTICIPATED IN Q4 2020.ARCA BIOPHARMA INC - TRIAL TO ENROLL APPROXIMATELY 100 PATIENTS HOSPITALIZED WITH COVID-19.ARCA BIOPHARMA INC - STUDY TOPLINE DATA ANTICIPATED Q2 2021.  Full Article

ARCA Biopharma Announces Promotion Of Chief Medical Officer & Vice President, Regulatory Affairs & Quality
Tuesday, 6 Oct 2020 

Oct 5 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA ANNOUNCES PROMOTION OF CHIEF MEDICAL OFFICER AND VICE PRESIDENT, REGULATORY AFFAIRS & QUALITY.ARCA BIOPHARMA INC - ANNOUNCED PROMOTION OF DEBRA MARSHALL, MD, FACC TO CHIEF MEDICAL OFFICER.  Full Article

Arca Biopharma Announces Submission Of Ind Application To U.S. FDA For Ab201 As A Potential Treatment For Covid-19
Monday, 21 Sep 2020 

Sept 21 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA ANNOUNCES SUBMISSION OF IND APPLICATION TO U.S. FDA FOR AB201 AS A POTENTIAL TREATMENT FOR COVID-19.ARCA BIOPHARMA - PENDING FDA FEEDBACK, ANTICIPATES INITIATING PHASE 2B PORTION OF SEQUENTIAL PHASE 2B/3 CLINICAL EVALUATION OF AB201 AS EARLY AS Q4 OF THIS YEAR.  Full Article

Arca Biopharma Enters Into Amendment On Demand Sales Agreement With Jonestrading Institutional Services
Wednesday, 15 Jul 2020 

July 14 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA - ENTERED INTO AMENDMENT NO. 8 TO CAPITAL ON DEMAND SALES AGREEMENT WITH JONESTRADING INSTITUTIONAL SERVICES.ARCA BIOPHARMA - AMENDMENT INCREASED MAXIMUM OFFERING VALUE OF SHARES WHICH CO MAY ISSUE & SELL FROM TIME TO TIME TO $32.4 MILLION.ARCA BIOPHARMA - BELIEVES CASH & CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND OPERATIONS THROUGH END OF Q3 2021.  Full Article

ARCA Biopharma Reports Q1 Loss Per Share $0.83
Thursday, 7 May 2020 

May 6 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.83.ARCA BIOPHARMA - WILL NEED TO RAISE ADDITIONAL CAPITAL, AND/OR COMPLETE PARTNERSHIP OR OTHER TRANSACTION, TO FUND FUTURE OPERATIONS.  Full Article

Arca Biopharma Posts Q2 Loss Per Share Of $1.14
Friday, 2 Aug 2019 

Aug 1 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $1.14.PRECISION-AF CLINICAL TRIAL INITIATION ANTICIPATED IN Q1 OF 2020.CASH AND CASH EQUIVALENTS WERE $9.97 MILLION AS OF JUNE 30, 2019, COMPARED TO $6.6 MILLION AS OF DECEMBER 31, 2018.ARCA BIOPHARMA - WILL NEED TO RAISE ADDITIONAL CAPITAL, AND/OR COMPLETE PARTNERSHIP OR OTHER POSSIBLE STRATEGIC TRANSACTION, TO FUND FUTURE OPERATIONS.ARCA - WILL NEED TO RAISE ADDITIONAL CAPITAL, COMPLETE PARTNERSHIP OR OTHER POSSIBLE STRATEGIC TRANSACTION, TO DEVELOP GENCARO OR ANY OTHER PRODUCT CANDIDATES.  Full Article

Arca Biopharma Says Cash As Of March 31 To Be Sufficient To Fund Operations Through Q1 2020
Saturday, 29 Jun 2019 

June 28 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA SAYS ENTERED INTO AMENDMENT NO. 6 TO ITS CAPITAL ON DEMAND(TM)SALES AGREEMENT, DATED AS OF JANUARY 11, 2017 - SEC FILING.ARCA BIOPHARMA - AMENDMENT INCREASED MAXIMUM OFFERING VALUE OF SHARES OF CO'S STOCK WHICH CO MAY ISSUE, SELL UNDER AMENDED SALES AGREEMENT TO $17.5 MILLION.ARCA BIOPHARMA - BELIEVES CASH & CASH EQUIVALENTS AS OF MARCH 31, 2019 TO BE SUFFICIENT TO FUND OPERATIONS, AT CURRENT COST STRUCTURE, THROUGH Q1 2020.  Full Article

ARCA Biopharma Says Co Entered Into Amendment No. 5 To Its Capital On Demand(Tm)Sales Agreement, Dated As Of January 11, 2017
Tuesday, 21 May 2019 

May 20 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA INC - ENTERED INTO AMENDMENT NO. 5 TO ITS CAPITAL ON DEMAND(TM)SALES AGREEMENT, DATED AS OF JANUARY 11, 2017.ARCA BIOPHARMA - AMENDMENT INCREASED MAXIMUM AGGREGATE OFFERING VALUE OF SHARES OF STOCK WHICH COMAY ISSUE AND SELL BY $1 MILLION TO $16.8 MILLION.ARCA BIOPHARMA - BELIEVES ITS CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND ITS OPERATIONS THROUGH FISCAL YEAR ENDING DEC 31, 2019..  Full Article

Arca Biopharma Says Filed Amendment To Implement Reverse Split Of Common Stock
Thursday, 4 Apr 2019 

April 3 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA INC - FILED AMENDMENT TO IMPLEMENT AN EIGHTEEN-FOR-ONE REVERSE SPLIT OF ITS COMMON STOCK AS PREVIOUSLY AUTHORIZED.ARCA BIOPHARMA INC - REVERSE SPLIT WILL BE EFFECTIVE AS OF 5:01 P.M. EASTERN TIME ON APRIL 3.  Full Article

Arca Biopharma Has Cash And Cash Equivalents Totaling $6.6 Mln (Unaudited) As Of Dec. 31
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA INC - AS OF DECEMBER 31, 2018, HAD CASH AND CASH EQUIVALENTS TOTALING $6.6 MILLION (UNAUDITED).ARCA BIOPHARMA INC - BELIEVES THAT FUNDS WILL BE SUFFICIENT TO FUND ITS OPERATIONS, AT ITS PROJECTED COST STRUCTURE, THROUGH END OF Q2 OF 2019..  Full Article

BRIEF-ARCA Biopharma Files May Offer & Sell Shares Of Common Stock Of Up To $7.6 Mln

* ARCA BIOPHARMA FILES TO SAY MAY OFFER & SELL SHARES OF COMMON STOCK OF UP TO $7.6 MILLION THROUGH JONESTRADING - SEC FILING Source text (https://bit.ly/2BAX0a2) Further company coverage: